secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001193125-26-059551
Event type: litigation
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents
--------------------------------------------------------------------------------

- Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.
- Ruling affirms December 2023 District of New Jersey verdict; Corcept will consider further judicial review.
- CEO Joseph Belanoff expressed disappointment and said company will vigorously defend its rights.
- Patents cover methods used in treating Cushing's syndrome; generic entry would weaken Korlym's market exclusivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526059551/0001193125-26-059551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526059551/d25779d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-059551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer